View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 06, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Registrant Name	Galera Therapeutics, Inc.
Entity Central Index Key	0001563577
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	GRTX
Security Exchange Name	NASDAQ
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,882,097
Entity File Number	001-39114
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-1454898
Entity Address, Address Line One	2 W. Liberty Blvd #100
Entity Address, City or Town	Malvern
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19355
City Area Code	610
Local Phone Number	725-1500
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 15,882	$ 18,356
Short-term investments	88,527	93,934
Prepaid expenses and other current assets	3,989	5,280
Total current assets	108,398	117,570
Property and equipment, net	1,165	934
Acquired intangible asset	2,258	2,258
Goodwill	881	881
Right-of-use lease asset	675	815
Other assets	918	918
Total assets	114,295	123,376
Current liabilities:
Accounts payable	6,767	3,945
Accrued expenses	5,367	5,452
Lease liability	268	297
Total current liabilities	12,402	9,694
Royalty purchase liability	60,879	43,251
Lease liability, net of current portion	414	534
Deferred tax liability	289	289
Other liabilities	74
Total liabilities	74,058	53,768
Stockholders’ equity:
Preferred stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value: 200,000,000 shares authorized; 24,845,798 and 24,811,567 shares issued and outstanding at June 30, 2020 and December 31, 2019	25	25
Additional paid-in capital	238,320	230,895
Accumulated other comprehensive income	316	38
Accumulated deficit	(198,424)	(161,350)
Total stockholders’ equity	40,237	69,608
Total liabilities and stockholders’ equity	$ 114,295	$ 123,376

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized (shares)	10,000,000	10,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	200,000,000	200,000,000
Common stock, shares issued (shares)	24,845,798	24,811,567
Common stock, shares outstanding (shares)	24,845,798	24,811,567

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating expenses:
Research and development	$ 13,839	$ 9,515	$ 28,092	$ 18,017
General and administrative	3,874	1,756	7,439	3,650
Loss from operations	(17,713)	(11,271)	(35,531)	(21,667)
Other income (expenses):
Interest income	352	513	820	970
Interest expense	(1,295)	(736)	(2,390)	(1,175)
Foreign currency gain (loss)	(1)	(64)	27	(35)
Net loss	(18,657)	(11,558)	(37,074)	(21,907)
Accretion of redeemable convertible preferred stock to redemption value		(2,060)		(4,071)
Net loss attributable to common stockholders	$ (18,657)	$ (13,618)	$ (37,074)	$ (25,978)
Net loss per share of common stock, basic and diluted	$ (0.75)	$ (45.30)	$ (1.49)	$ (86.42)
Weighted-average shares of common stock outstanding, basic and diluted	24,832,264	300,597	24,823,644	300,597

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (18,657)	$ (11,558)	$ (37,074)	$ (21,907)
Unrealized gain (loss) on short-term investments	(370)	68	278	78
Comprehensive loss	$ (19,027)	$ (11,490)	$ (36,796)	$ (21,829)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Balance at Dec. 31, 2018	$ (104,820)				$ 3	$ (104,823)
Balance (in shares) at Dec. 31, 2018		96,385,795
Balance at Dec. 31, 2018		$ 165,902
Balance (in shares) at Dec. 31, 2018			300,597
Share-based compensation expense	499			$ 499
Accretion of redeemable convertible preferred stock to redemption value	(2,011)	$ 2,011		(499)		(1,512)
Unrealized gain (loss) on short-term investments	10				10
Net loss	(10,349)					(10,349)
Balance at Mar. 31, 2019	(116,671)				13	(116,684)
Balance (in shares) at Mar. 31, 2019		96,385,795
Balance at Mar. 31, 2019		$ 167,913
Balance (in shares) at Mar. 31, 2019			300,597
Balance at Dec. 31, 2018	(104,820)				3	(104,823)
Balance (in shares) at Dec. 31, 2018		96,385,795
Balance at Dec. 31, 2018		$ 165,902
Balance (in shares) at Dec. 31, 2018			300,597
Unrealized gain (loss) on short-term investments	78
Net loss	(21,907)
Balance at Jun. 30, 2019	(129,656)				81	(129,737)
Balance (in shares) at Jun. 30, 2019		96,385,795
Balance at Jun. 30, 2019		$ 169,973
Balance (in shares) at Jun. 30, 2019			300,597
Balance at Mar. 31, 2019	(116,671)				13	(116,684)
Balance (in shares) at Mar. 31, 2019		96,385,795
Balance at Mar. 31, 2019		$ 167,913
Balance (in shares) at Mar. 31, 2019			300,597
Share-based compensation expense	565			565
Accretion of redeemable convertible preferred stock to redemption value	(2,060)	$ 2,060		(565)		(1,495)
Unrealized gain (loss) on short-term investments	68				68
Net loss	(11,558)					(11,558)
Balance at Jun. 30, 2019	(129,656)				81	(129,737)
Balance (in shares) at Jun. 30, 2019		96,385,795
Balance at Jun. 30, 2019		$ 169,973
Balance (in shares) at Jun. 30, 2019			300,597
Balance at Dec. 31, 2019	$ 69,608		$ 25	230,895	38	(161,350)
Balance (in shares) at Dec. 31, 2019	24,811,567		24,811,567
Share-based compensation expense	$ 1,210			1,210
Exercise of stock options	9			9
Exercise of stock options, shares			8,503
Unrealized gain (loss) on short-term investments	648				648
Net loss	(18,417)					(18,417)
Balance at Mar. 31, 2020	53,058		$ 25	232,114	686	(179,767)
Balance (in shares) at Mar. 31, 2020			24,820,070
Balance at Dec. 31, 2019	$ 69,608		$ 25	230,895	38	(161,350)
Balance (in shares) at Dec. 31, 2019	24,811,567		24,811,567
Exercise of stock options, shares	34,231
Unrealized gain (loss) on short-term investments	$ 278
Net loss	(37,074)
Balance at Jun. 30, 2020	$ 40,237		$ 25	238,320	316	(198,424)
Balance (in shares) at Jun. 30, 2020	24,845,798		24,845,798
Balance at Mar. 31, 2020	$ 53,058		$ 25	232,114	686	(179,767)
Balance (in shares) at Mar. 31, 2020			24,820,070
Issuance of common stock warrants	4,712			4,712
Share-based compensation expense	1,453			1,453
Exercise of stock options	41			41
Exercise of stock options, shares			25,728
Unrealized gain (loss) on short-term investments	(370)				(370)
Net loss	(18,657)					(18,657)
Balance at Jun. 30, 2020	$ 40,237		$ 25	$ 238,320	$ 316	$ (198,424)
Balance (in shares) at Jun. 30, 2020	24,845,798		24,845,798

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities:
Net loss	$ (37,074)	$ (21,907)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	175	113
Noncash interest expense	2,390	1,175
Share-based compensation expense	2,663	1,064
Reserve for tax incentive receivable		241
Deferred rent		10
Changes in operating assets and liabilities:
Tax incentive receivable		629
Prepaid expenses and other current assets	1,291	(1,209)
Other assets	140	181
Accounts payable	2,822	1,352
Accrued expense and other liabilities	(210)	(133)
Cash used in operating activities	(27,803)	(18,484)
Investing activities:
Purchases of short-term investments	(42,065)	(49,798)
Proceeds from sales of short-term investments	47,750	51,500
Purchase of property and equipment	(406)	(507)
Cash provided by investing activities	5,279	1,195
Financing activities:
Proceeds from royalty purchase agreement	20,000	20,000
Payment of deferred offering costs		(1,327)
Proceeds from exercise of stock options	50
Cash provided by financing activities	20,050	18,673
Net increase (decrease) in cash and cash equivalents	(2,474)	1,384
Cash and cash equivalents at beginning of period	18,356	14,811
Cash and cash equivalents at end of period	15,882	16,195
Supplemental schedule of non-cash financing activities:
Issuance of warrants in conjunction with amendment to the royalty purchase agreement	4,712
Accretion of redeemable convertible preferred stock to redemption value		4,071
Deferred offering costs included in accounts payable and accrued expenses		420
Purchase of property and equipment included in accounts payable and accrued expenses	$ 36
Initial recognition of operating lease right-of-use asset and operating lease liability		$ 1,084

Organization and Description of Business

6 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization and Description of Business

1.	Organization and description of business

Galera Therapeutics, Inc. was incorporated as a Delaware corporation on November 19, 2012 (inception) and together with its subsidiaries, (the Company, or Galera) is a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (GC4419, also referred to as avasopasem), is a potent and highly selective small molecule dismutase mimetic being developed for the reduction of severe oral mucositis (SOM). In February 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to avasopasem for the reduction of SOM induced by radiotherapy with or without systemic therapy. The Company is currently evaluating avasopasem in a Phase 3 registrational trial (referred to as the ROMAN trial) for its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in a Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with head and neck cancer undergoing standard-of-care radiotherapy and in a Phase 2a trial for its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer. In addition to developing avasopasem for the reduction of normal tissue toxicity from radiotherapy, the Company is developing its dismutase mimetics to increase the anti-cancer efficacy of higher daily doses of radiotherapy, including stereotactic body radiation therapy (SBRT). The Company’s second dismutase mimetic product candidate, GC4711, is being developed to increase the anti-cancer efficacy of SBRT and has successfully completed Phase 1 trials of intravenous GC4711 in healthy volunteers. The Company plans to leverage its observations from the ongoing avasopasem SBRT pilot Phase 1b/2a trial in locally advanced pancreatic cancer (LAPC) to prepare a GC4711 SBRT combination Phase 1b/2a safety and anti-cancer efficacy trial in non-small cell lung cancer (NSCLC).

Liquidity

The Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $198.4 million as of June 30, 2020. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company expects its existing cash, cash equivalents and short-term investments, together with the expected payments from Blackstone Life Sciences (formerly known as Clarus Ventures) in the amount of $57.5 million upon the achievement of certain clinical enrollment milestones in the ROMAN trial and the anti-cancer program in combination with SBRT under the Royalty Agreement and the Amendment (each as defined below), will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2022. See Notes 6 and 10.

On November 12, 2019, the Company completed an initial public offering (IPO) of its common stock, which resulted in the issuance and sale of 5,000,000 shares of its common stock at a public offering price of $12.00 per share, generating net proceeds of $53.0 million after deducting underwriting discounts and other offering costs. On December 9, 2019, in connection with the partial exercise of the over-allotment option granted to the underwriters of the Company's IPO, 445,690 additional shares of common stock were sold at the IPO price of $12.00 per share, generating net proceeds of approximately $5.0 million after deducting underwriting discounts and other offering costs. Upon the closing of the IPO, all outstanding shares of the Company’s Series A, Series B and Series C redeemable convertible preferred stock were automatically converted into 19,061,502 shares of the Company’s common stock.

Basis of Presentation and Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies

2.	Basis of presentation and significant accounting policies

The summary of significant accounting policies disclosed in the Company’s annual consolidated financial statements for the years ended December 31, 2019 and 2018 included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 10, 2020 have not materially changed, except as set forth below.

Basis of presentation and consolidation

The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).

In the opinion of management, the accompanying interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of June 30, 2020 and its results of operations for the three and six months ended June 30, 2020 and 2019, and statements of changes in redeemable convertible preferred stock and stockholder’s equity (deficit) and cash flows for the six months ended June 30, 2020 and 2019. Operating results for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020, or for any future period. The interim consolidated financial statements, presented herein, do not contain the required disclosures under U.S. GAAP for annual financial statements. Therefore, these interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December 31, 2019, included in the Company’s annual report on Form 10-K and filed with the SEC on March 10, 2020.

Use of estimates

The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include the fair value of common stock, prior to the IPO, share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expenses.

The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. Management has made estimates regarding the impact of COVID-19 within the Company’s financial disclosures and there may be changes to those estimates in future periods. Actual results may differ from these estimates.

Net loss per share

Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	June 30,
	2020		2019
Stock options		4,596,357		3,129,537
Common stock warrants		550,661		—
Redeemable convertible preferred stock		—		19,061,502
		5,147,018		22,191,039

Amounts in the above table reflect the common stock equivalents for the redeemable convertible preferred stock.

COVID-19

The COVID-19 pandemic and related precautions have directly or indirectly impacted the timeline for some of the Company’s clinical trials. In April 2020, the Company delayed the initiation of the Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, due to concerns with patient enrollment. In June 2020, the Company dosed the first patient in the trial. This trial was originally expected to enroll up to 70 patients and contribute to the safety database for avasopasem in patients with HNC receiving radiotherapy. The Company continues to monitor the COVID-19 pandemic in Europe regarding the enrollment prospects for this trial. As a result of the delay in initiating the trial in Europe, the target enrollment for the ROMAN trial was increased to approximately 450 patients in order to ensure the Company is positioned to maintain the planned size of the safety database in a timely manner, with completion of enrollment expected in the first half of 2021 and data expected in the second half of 2021, subject to the continuing impact of the COVID-19 pandemic on the Company’s business. With this change in the ROMAN trial, the assumptions underlying the Company’s calculation of interest expense on its royalty purchase liability have changed. The Company imputes interest expense on its royalty purchase obligations by estimating risk adjusted future royalty payments over the term of the Royalty Agreement which takes into consideration the probability and timing of obtaining FDA approval and the potential future revenue from commercializing its product candidates.

Recent accounting pronouncements

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which removes and modifies some existing disclosure requirements and adds others. This ASU is effective for all entities for fiscal years beginning after December 15, 2019, including interim periods therein. The Company adopted this ASU on January 1, 2020 and it did not have an impact on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Service Arrangement that is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This guidance is effective for fiscal years beginning after December 15, 2019, including interim periods therein, The Company adopted this guidance on January 1, 2020 and it did not have a material impact on the Company’s consolidated financial statements.

Fair Value Measurements

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

3.	Fair value measurements

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

•

Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

•

Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

•

Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis (amounts in thousands):

	June 30, 2020
	(Level 1)		(Level 2)		(Level 3)
Assets
Money market funds and U.S. Treasury obligations (included in cash equivalents)	$	15,093	$	—	$	—
Short-term investments	$	88,527	$	—	$	—

	December 31, 2019
	(Level 1)		(Level 2)		(Level 3)
Assets
Money market funds and U.S. Treasury obligations (included in cash equivalents)	$	17,447	$	—	$	—
Short-term investments	$	93,934	$	—	$	—

There were no changes in valuation techniques during the six months ended June 30, 2020. The Company’s short-term investment instruments are classified using Level 1 inputs within the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Property and Equipment

6 Months Ended

Jun. 30, 2020

Property Plant And Equipment [Abstract]

Property and Equipment

4.	Property and equipment

Property and equipment consist of (amounts in thousands):

	June 30, 2020			December 31, 2019
Laboratory equipment	$	1,114		$	748
Computer hardware and software		229			218
Leasehold improvements		264			262
Furniture and fixtures		173			147
Property and equipment, gross		1,780			1,375
Less: Accumulated depreciation		(615	)		(441	)
Property and equipment, net	$	1,165		$	934

Depreciation expense was $0.2 million and $0.1 million for the six months ended June 30, 2020 and 2019, respectively.

Accrued Expenses

6 Months Ended

Jun. 30, 2020

Payables And Accruals [Abstract]

Accrued Expenses

5.	Accrued expenses

Accrued expenses consist of (amounts in thousands):

	June 30, 2020		December 31, 2019
Compensation and related benefits	$	1,408	$	1,160
Research and development expenses		3,661		3,882
Professional fees and other expenses		298		410
	$	5,367	$	5,452

Royalty Purchase Liability

6 Months Ended

Jun. 30, 2020

Royalty Purchase Liability [Abstract]

Royalty Purchase Liability

6.	Royalty purchase liability

In November 2018, the Company entered into an Amended and Restated Purchase and Sale Agreement (the Royalty Agreement), with Clarus IV Galera Royalty AIV, L.P., Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P. and Clarus IV-D, L.P. (collectively, Blackstone or Blackstone Life Sciences). Pursuant to the Royalty Agreement, Blackstone agreed to pay up to $80.0 million (the Royalty Purchase Price) in four tranches of $20.0 million each upon the achievement of specific Phase 3 clinical trial patient enrollment milestones. The Company received the first tranche of the Royalty Purchase Price in November 2018. In April 2019, the Company received $20.0 million in connection with the achievement of the second milestone under the Royalty Agreement. In February 2020, the Company received a $20.0 million payment in connection with the achievement of the third milestone under the Royalty Agreement.

The Company accounts for the Royalty Agreement as a debt instrument. The $60.0 million proceeds from the first three tranches under the Royalty Agreement have been recorded as a liability on the Company’s consolidated balance sheets. Interest expense is imputed based on the estimated royalty repayment period described below which results in a corresponding increase in the liability balance. The Company recognized $2.4 million and $1.2 million in noncash interest expense during the six months ended June 30, 2020 and 2019, respectively. As of June 30, 2020, the effective interest rate was 8.0%.

In May 2020, the Company entered into Amendment No. 1 to the Royalty Agreement (the Amendment) with Clarus IV Galera Royalty AIV, L.P. (the Blackstone Purchaser). The Blackstone Purchaser is affiliated with Blackstone Life Sciences, the successor in interest to Clarus Ventures. The Amendment increased the Royalty Purchase Price by $37.5 million, to $117.5 million by increasing the fourth tranche from $20.0 million to $37.5 million and adding a new $20.0 million tranche upon the achievement of an additional clinical enrollment milestone. The Company accounted for the Amendment as a debt modification and is amortizing fees paid to the Blackstone Purchaser related to the Amendment over the estimated term of the royalty purchase liability utilizing the effective-interest method.

Pursuant to the amended Royalty Agreement, in connection with the payment of each tranche of the Royalty Purchase Price, the Company has agreed to sell, convey, transfer and assign to Blackstone all of its right, title and interest in a high single-digit percentage of (i) worldwide net sales of avasopasem and GC4711 (collectively, the Products) and (ii) all amounts received by the Company or its affiliates, licensees and sublicensees with respect to Product-related damages (collectively, the Product Payments) during the Royalty Period. The Royalty Period means, on a Product-by-Product and country-by-country basis, the period of time commencing on the commercial launch of such Product in such country and ending on the latest to occur of (i) the 12th anniversary of such commercial launch, (ii) the expiration of all valid claims of the Company’s patents covering such Product in such country, and (iii) the expiration of regulatory data protection or market exclusivity or similar regulatory protection afforded by the health authorities in such country, to the extent such protection or exclusivity effectively prevents generic versions of such Product from entering the market in such country.

The amended Royalty Agreement will remain in effect until the date on which the aggregate amount of the Product Payments paid to Blackstone exceeds a fixed single-digit multiple of the actual amount of the Royalty Purchase Price received by the Company, unless earlier terminated pursuant to the mutual written agreement of the Company and Blackstone.

Upon execution of the Amendment, the Company issued common stock warrants to the Blackstone Purchaser to purchase an aggregate of 550,661 shares of the Company’s common stock with an exercise price of $13.62 per share, each of which will become exercisable upon the receipt by Galera of the applicable specified milestone payment. The issued warrants expire six years after the initial exercise dates. The warrants are equity-classified and were valued at $4.7 million using the Black-Scholes valuation technique. The warrants were recorded as a discount to the royalty purchase liability. The Company will amortize the debt discount to interest expense over the estimated term of the royalty purchase liability utilizing the effective-interest method.

Leases

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

The Company has non-cancelable operating leases for office and laboratory space in Malvern, Pennsylvania and St. Louis, Missouri which, as of June 30, 2020, have remaining lease terms of approximately 3.0 and 0.9 years, respectively. The Company adopted ASC 842 on January 1, 2019 resulting in the recognition of a current operating lease liability of $0.3 million and a noncurrent operating lease liability of $0.8 million with a corresponding $1.1 million right-of-use (ROU) asset, which was based on the present value of the minimum rental payments of the lease. The discount rate used to account for the Company’s operating lease under ASC 842 is the Company’s estimated incremental borrowing rate of 5.3%.

Supplemental balance sheet information related to leases was as follows:

	June 30,		December 31,
	2020		2019
Operating Leases
Operating lease right-of-use assets	$	675	$	815

Other current liabilities		268		297
Operating lease liabilities		414		534
Total operating lease liabilities	$	682	$	831

The components of lease expense were as follows:

	Three months ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Operating lease costs
Operating lease rental expense	$	75	$	69	$	149	$	121
Interest on lease liabilities		9		13		19		27
Total operating lease liabilities	$	84	$	82	$	168	$	148

Supplemental cash flow information related to leases was as follows:

	Six Months Ended June 30,
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	226	$	206
Right-of-use assets obtained in exchange for lease obligation
Operating leases		—		1,084

Future minimum rental payments under the Company’s non-cancelable operating leases were as follows as of June 30, 2020 (amounts in thousands):

Remainder of 2020	$	164
2021		259
2022		260
2023		44
Total		727
Less: imputed interest		(45	)
	$	682

Share-based Compensation

6 Months Ended

Jun. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-based Compensation

8.	Share-based compensation

In connection with the Company’s IPO, in November 2019, the Company’s board of directors adopted and the Company’s stockholders approved the Galera Therapeutics, Inc. 2019 Incentive Award Plan (the 2019 Plan), which became effective upon the effectiveness of the registration statement on Form S-1 for the IPO. Upon effectiveness of the 2019 Plan, the Company ceased granting new awards under the Prior Plan (as defined herein).

The 2019 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. The number of shares of common stock initially available for issuance under the 2019 Plan is 1,948,970 shares of common stock plus the number of shares subject to awards outstanding under the Prior Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company on or after the effective date of the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan is subject to an annual increase on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029 equal to the lesser of (i) 4% of the Company’s outstanding shares of common stock on the final day of the immediately preceding calendar year, and (ii) such smaller number of shares of common stock as determined by the Company’s board of directors. Pursuant to this provision, the Company added 992,463 shares to the total shares available for issuance under the 2019 Plan effective January 1, 2020. The maximum number of shares of common stock that may be issued under the 2019 Plan upon the exercise of incentive stock options is 14,130,029.

In November 2019, the Company’s board of directors adopted and the Company’s stockholders approved the Galera Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the ESPP). The ESPP allows employees to buy Company stock through after-tax payroll deductions at a discount from market value. The number of shares of common stock initially available for issuance under the ESPP is 243,621 shares of common stock plus an annual increase on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029 equal to the lesser of (i) 1% of the Company’s outstanding shares of common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Company’s board of directors, provided that not more than 3,288,886 shares of common stock may be issued under the ESPP. Pursuant to this provision, the Company added 248,115 shares to the total shares available for issuance under the ESPP effective January 1, 2020.

In November 2012, the Company adopted the Equity Incentive Plan (the Prior Plan). The total number of shares authorized under the Prior Plan as of December 31, 2019 was 3,038,259, all of which were subject to outstanding awards. No further grants will be made under the Prior Plan; however, the Prior Plan continues to govern awards that are outstanding under it.

The Company’s stock option awards vest based on the terms in the governing agreements and generally vest over four years and have a term of 10 years.

Share-based compensation expense was as follows for the three and six months ended June 30, 2020 and 2019 (in thousands):

	Three months ended June 30,				Six months ended June 30,
	2020		2019		2020		2019
Research and development	$	668	$	275	$	1,262	$	513
General and administrative		785		290		1,401		551
	$	1,453	$	565	$	2,663	$	1,064

The following table summarizes the activity related to stock option grants for the six months ended June 30, 2020:

	Shares			Weighted average exercise price per share		Weighted- average remaining contractual life (years)
Outstanding at January 1, 2020		3,537,946		$	5.17
Granted		1,108,573			14.04
Exercised		(34,231	)		1.48
Forfeited		(15,931	)		12.00
Outstanding at June 30, 2020		4,596,357		$	7.32		7.4
Vested and exercisable at June 30, 2020		2,329,259		$	3.51		5.7
Vested and expected to vest at June 30, 2020		4,596,357		$	7.32		7.4

As of June 30, 2020, the unrecognized compensation cost was $18.0 million and will be recognized over an estimated weighted-average amortization period of 3.2 years. The aggregate intrinsic value of options outstanding and options exercisable as of June 30, 2020 was $9.7 million and $9.3 million, respectively. Options granted during the six months ended June 30, 2020 and 2019 had weighted-average grant-date fair values of $10.45 and $5.51 per share, respectively.

The fair value of options is estimated using the Black-Scholes option pricing model, which takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at the grant date, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The fair value of stock options during the six months ended June 30, 2020 and 2019 was determined using the methods and assumptions discussed below.

•

The expected term of employee stock options with service-based vesting is determined using the “simplified” method, as prescribed in SEC’s Staff Accounting Bulletin (SAB) No. 107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data. The expected term of nonemployee options is equal to the contractual term.

•

The expected stock price volatility is based on historical volatilities of comparable public entities within the Company’s industry which were commensurate with the expected term assumption as described in SAB No. 107.

•

The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term.

•

The expected dividend yield is 0% because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.

•

Prior to the Company’s IPO, its board of directors had periodically estimated the fair value of the Company’s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants 2013 Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Since the closing of the IPO, the Company’s board of directors has determined the price per share value of the Company’s common stock based on the closing price as reported by the NASDAQ Global Market on the date of the grant.

The grant date fair value of each option grant was estimated throughout the quarter using the Black-Scholes option-pricing model using the following weighted-average assumptions:

	Six months ended June 30,
	2020			2019
Expected term (in years)		6.2			6.1
Expected stock price volatility		89.2	%		90.0	%
Risk-free interest rate		1.26	%		2.55	%
Expected dividend yield		0	%		0	%

Related Party Transactions

6 Months Ended

Jun. 30, 2020

Related Party Transactions

9.	Related party transactions

IntellectMap provides advisory services to the Company. The chief executive officer of IntellectMap is the brother of the Company’s chief executive officer. Fees incurred by us with respect to IntellectMap during the six months ended June 30, 2020 and 2019 were $0.2 million and $0.1 million, respectively.

Basis of Presentation and Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Liquidity

Basis of Presentation and Consolidation

Basis of presentation and consolidation

Use of Estimates

Use of estimates

Net Loss Per Share

Net loss per share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	June 30,
	2020		2019
Stock options		4,596,357		3,129,537
Common stock warrants		550,661		—
Redeemable convertible preferred stock		—		19,061,502
		5,147,018		22,191,039

Amounts in the above table reflect the common stock equivalents for the redeemable convertible preferred stock.

Recent Accounting Pronouncements

COVID-19

Recent accounting pronouncements

Basis of Presentation and Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock Outstanding

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	June 30,
	2020		2019
Stock options		4,596,357		3,129,537
Common stock warrants		550,661		—
Redeemable convertible preferred stock		—		19,061,502
		5,147,018		22,191,039

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis (amounts in thousands):

	June 30, 2020
	(Level 1)		(Level 2)		(Level 3)
Assets
Money market funds and U.S. Treasury obligations (included in cash equivalents)	$	15,093	$	—	$	—
Short-term investments	$	88,527	$	—	$	—

	December 31, 2019
	(Level 1)		(Level 2)		(Level 3)
Assets
Money market funds and U.S. Treasury obligations (included in cash equivalents)	$	17,447	$	—	$	—
Short-term investments	$	93,934	$	—	$	—

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2020

Property Plant And Equipment [Abstract]

Schedule of Property Plant and Equipment

Property and equipment consist of (amounts in thousands):

	June 30, 2020			December 31, 2019
Laboratory equipment	$	1,114		$	748
Computer hardware and software		229			218
Leasehold improvements		264			262
Furniture and fixtures		173			147
Property and equipment, gross		1,780			1,375
Less: Accumulated depreciation		(615	)		(441	)
Property and equipment, net	$	1,165		$	934

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2020

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consist of (amounts in thousands):

	June 30, 2020		December 31, 2019
Compensation and related benefits	$	1,408	$	1,160
Research and development expenses		3,661		3,882
Professional fees and other expenses		298		410
	$	5,367	$	5,452

Leases (Tables)

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases was as follows:

	June 30,		December 31,
	2020		2019
Operating Leases
Operating lease right-of-use assets	$	675	$	815

Other current liabilities		268		297
Operating lease liabilities		414		534
Total operating lease liabilities	$	682	$	831

Summary of Components of Lease Expense

The components of lease expense were as follows:

	Three months ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Operating lease costs
Operating lease rental expense	$	75	$	69	$	149	$	121
Interest on lease liabilities		9		13		19		27
Total operating lease liabilities	$	84	$	82	$	168	$	148

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases was as follows:

	Six Months Ended June 30,
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	226	$	206
Right-of-use assets obtained in exchange for lease obligation
Operating leases		—		1,084

Summary of Future Minimum Rental Payments Under Non Cancelable Operating Leases

Future minimum rental payments under the Company’s non-cancelable operating leases were as follows as of June 30, 2020 (amounts in thousands):

Remainder of 2020	$	164
2021		259
2022		260
2023		44
Total		727
Less: imputed interest		(45	)
	$	682

Share-based Compensation (Tables)

6 Months Ended

Jun. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Share-based Compensation Expense

Share-based compensation expense was as follows for the three and six months ended June 30, 2020 and 2019 (in thousands):

	Three months ended June 30,				Six months ended June 30,
	2020		2019		2020		2019
Research and development	$	668	$	275	$	1,262	$	513
General and administrative		785		290		1,401		551
	$	1,453	$	565	$	2,663	$	1,064

Summary of Activity Related to Stock Option Grants

The following table summarizes the activity related to stock option grants for the six months ended June 30, 2020:

	Shares			Weighted average exercise price per share		Weighted- average remaining contractual life (years)
Outstanding at January 1, 2020		3,537,946		$	5.17
Granted		1,108,573			14.04
Exercised		(34,231	)		1.48
Forfeited		(15,931	)		12.00
Outstanding at June 30, 2020		4,596,357		$	7.32		7.4
Vested and exercisable at June 30, 2020		2,329,259		$	3.51		5.7
Vested and expected to vest at June 30, 2020		4,596,357		$	7.32		7.4

Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model

The grant date fair value of each option grant was estimated throughout the quarter using the Black-Scholes option-pricing model using the following weighted-average assumptions:

	Six months ended June 30,
	2020			2019
Expected term (in years)		6.2			6.1
Expected stock price volatility		89.2	%		90.0	%
Risk-free interest rate		1.26	%		2.55	%
Expected dividend yield		0	%		0	%

Organization and description of business - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			6 Months Ended
	Dec. 09, 2019	Nov. 12, 2019	Jun. 30, 2020	Dec. 31, 2019
Organization And Description Of Business [Line Items]
Date of incorporation			Nov. 19, 2012
Accumulated deficit			$ (198,424)	$ (161,350)
Expected payments to be received from royalty purchase agreement			$ 57,500
Common stock, shares issued (shares)			24,845,798	24,811,567
Redeemable Convertible Preferred Stock
Organization And Description Of Business [Line Items]
Shares issued upon conversion		19,061,502
IPO
Organization And Description Of Business [Line Items]
Common stock, shares issued (shares)		5,000,000
Public offering price		$ 12.00
Net proceeds from stock offering		$ 53,000
Over-allotment option
Organization And Description Of Business [Line Items]
Common stock, shares issued (shares)	445,690
Public offering price	$ 12.00
Net proceeds from stock offering	$ 5,000

Basis of Presentation and Significant Accounting Policies - Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock Outstanding (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities excluded from computation of earnings per share	5,147,018	22,191,039
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities excluded from computation of earnings per share	4,596,357	3,129,537
Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities excluded from computation of earnings per share	550,661
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities excluded from computation of earnings per share		19,061,502

Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Level 1 \| Money Market Funds and U.S. Treasury Obligations
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents, at fair value	$ 15,093	$ 17,447
Level 1 \| Short- Term Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	88,527	93,934
Level 2 \| Money Market Funds and U.S. Treasury Obligations
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents, at fair value	0	0
Level 2 \| Short- Term Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	0	0
Level 3 \| Money Market Funds and U.S. Treasury Obligations
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents, at fair value	0	0
Level 3 \| Short- Term Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	$ 0	$ 0

Fair Value Measurements - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020 USD ($)
Fair Value Disclosures [Abstract]
Changes in valuation techniques	$ 0

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,780	$ 1,375
Less: Accumulated depreciation	(615)	(441)
Property and equipment, net	1,165	934
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,114	748
Computer Hardware and Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	229	218
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	264	262
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 173	$ 147

Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Depreciation	$ 175	$ 113

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Compensation and related benefits	$ 1,408	$ 1,160
Research and development expenses	3,661	3,882
Professional fees and other expenses	298	410
Accrued expenses	$ 5,367	$ 5,452

Royalty Purchase Liability - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			6 Months Ended
	Feb. 29, 2020	Apr. 30, 2019	Nov. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	May 31, 2020	Dec. 31, 2019
Royalty Purchase Liability [Line Items]
Total agreed amount of royalty purchase price				$ 60,879			$ 43,251
Royalty purchase price				20,000	$ 20,000
Noncash interest expense				2,390	1,175
Royalty purchase liability				60,879			$ 43,251
Royalty Agreements
Royalty Purchase Liability [Line Items]
Total agreed amount of royalty purchase price			$ 80,000
Royalty purchase price				60,000
Noncash interest expense				$ 2,400	$ 1,200
Effective interest rate				8.00%
Outstanding amount of royalty agreement						$ 20,000
Royalty purchase liability			80,000
Royalty Agreements \| First Tranche
Royalty Purchase Liability [Line Items]
Royalty purchase price			$ 20,000
Royalty Agreements \| Second Tranche
Royalty Purchase Liability [Line Items]
Royalty purchase price		$ 20,000
Royalty Agreements \| Third Tranche
Royalty Purchase Liability [Line Items]
Royalty purchase price	$ 20,000
Amended Royalty Agreements
Royalty Purchase Liability [Line Items]
Total agreed amount of royalty purchase price						117,500
Outstanding amount of royalty agreement						37,500
Royalty purchase liability						$ 117,500
Class of warrant, shares issued						550,661
Common stock, exercise price per share						$ 13.62
Fair value of equity classified warrants						$ 4,700
Amended Royalty Agreements \| Fifth Tranche
Royalty Purchase Liability [Line Items]
Outstanding amount of royalty agreement						$ 20,000

Leases - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Lessee Lease Description [Line Items]
Operating lease liability, non current	$ 414	$ 534
Operating lease, right-of-use asset	675	$ 815
ASC 842
Lessee Lease Description [Line Items]
Operating lease liability, current	300
Operating lease liability, non current	800
Operating lease, right-of-use asset	$ 1,100
Operating lease, discount rate	5.30%
ASC 842 \| Office
Lessee Lease Description [Line Items]
Non-cancelable operating lease, term	3 years
ASC 842 \| Laboratory Space
Lessee Lease Description [Line Items]
Non-cancelable operating lease, term	10 months 24 days

Leases - Summary of Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease right-of-use assets	$ 675	$ 815
Other current liabilities	268	297
Operating lease liabilities	414	534
Total operating lease liabilities	$ 682	$ 831

Leases - Summary of Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Operating lease rental expense	$ 75	$ 69	$ 149	$ 121
Interest on lease liabilities	9	13	19	27
Total operating lease liabilities	$ 84	$ 82	$ 168	$ 148

Leases - Summary of Supplemental Cash Flow Information Related to Lease (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Operating cash flows from operating leases	$ 226	$ 206
Right-of-use assets obtained in exchange for lease obligation
Operating leases		$ 1,084

Leases - Summary of Future Minimum Rental Payments Under Non Cancelable Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Remainder of 2020	$ 164
2021	259
2022	260
2023	44
Total	727
Less: imputed interest	(45)
Operating lease liabilities	$ 682	$ 831

Share-based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	6 Months Ended
	Nov. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost		$ 18.0
Estimated recognition weighted-average amortization period		3 years 2 months 12 days
Aggregate intrinsic value of options outstanding		$ 9.7
Aggregate intrinsic value of options exercisable		$ 9.3
Weighted-average grant-date fair values of options granted		$ 10.45	$ 5.51
Expected dividend yield		0.00%	0.00%
2019 Incentive Award Plan \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares of common stock initially available for issuance	1,948,970
Percentage of shares of common stock outstanding	4.00%
Number of additional shares available for issuance	992,463
2019 Incentive Award Plan \| Common Stock \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued under the plan	14,130,029
2019 Employee Stock Purchase Plan \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of shares of common stock outstanding	1.00%
Number of additional shares available for issuance	248,115
Number of shares available for issuance	243,621
2019 Employee Stock Purchase Plan \| Common Stock \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued under the plan	3,288,886
2012 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for issuance		0
Number of shares authorized				3,038,259
Vesting period		4 years
Term of award		10 years

Share-based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 1,453	$ 565	$ 2,663	$ 1,064
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	668	275	1,262	513
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 785	$ 290	$ 1,401	$ 551

Share-based Compensation - Summary of Activity Related to Stock Option Grants (Details) - $ / shares	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares, Outstanding beginning balance	3,537,946
Shares, Granted	1,108,573
Shares, Exercised	(34,231)
Shares, Forfeited	(15,931)
Shares, Outstanding ending balance	4,596,357
Shares, Vested and exercisable	2,329,259
Shares, Vested and expected to vest	4,596,357
Weighted average exercise price per share, Outstanding beginning balance	$ 5.17
Weighted average exercise price per share, Granted	14.04
Weighted average exercise price per share, Exercised	1.48
Weighted average exercise price per share, Forfeited	12.00
Weighted average exercise price per share, Outstanding ending balance	7.32
Weighted average exercise price per share, Vested and exercisable	3.51
Weighted average exercise price per share, Vested and expected to vest	$ 7.32
Weighted average remaining contractual life, Outstanding	7 years 4 months 24 days
Weighted average remaining contractual life, Vested and exercisable	5 years 8 months 12 days
Weighted average remaining contractual life, Vested and expected to vest	7 years 4 months 24 days

Share-based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Details)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]
Expected term (in years)	6 years 2 months 12 days	6 years 1 month 6 days
Expected stock price volatility	89.20%	90.00%
Risk-free interest rate	1.26%	2.55%
Expected dividend yield	0.00%	0.00%

Related Party Transactions (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
IntellectMap
Related Party Transaction [Line Items]
Advisory services fees	$ 0.2	$ 0.1